Introduction
============

Tumor angiogenesis is a complex process that is crucial for tumor growth, invasion, and metastasis.[@b1-ott-8-2361]--[@b3-ott-8-2361] During the past decades, many new agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs) have proven to be a successful strategy in patients with cancer. Until now, the US Food and Drug Administration has approved a number of VEGFR tyrosine kinase inhibitors (TKIs) in multiple indications: sunitinib, sorafenib, pazopanib, and axitinib have been approved for patients with metastatic renal cell carcinoma (RCC).[@b4-ott-8-2361]--[@b8-ott-8-2361] Moreover, sunitinib has been approved for pancreatic neuroendocrine tumors[@b9-ott-8-2361] and refractory gastrointestinal stromal tumors (GISTs),[@b10-ott-8-2361] and sorafenib has been approved for advanced hepatocellular carcinoma (HCC)[@b11-ott-8-2361] and radioiodine-refractory differentiated thyroid carcinoma.[@b12-ott-8-2361] Additionally, vandetanib has been approved for symptomatic or progressive medullary thyroid cancer,[@b13-ott-8-2361] and regorafenib has been approved for refractory advanced colorectal cancer[@b14-ott-8-2361] and GISTs.[@b15-ott-8-2361]

However, the toxicity profiles of VEGFR-TKIs are unique compared with the adverse effects typically associated with traditional cytotoxic anticancer therapies. They include mucocutaneous adverse events,[@b16-ott-8-2361]--[@b19-ott-8-2361] liver dysfunction,[@b20-ott-8-2361]--[@b23-ott-8-2361] gastrointestinal perforation,[@b24-ott-8-2361],[@b25-ott-8-2361] and cardiovascular toxicities.[@b26-ott-8-2361]--[@b33-ott-8-2361] Additionally, severe infections (≥grade 3) associated with VEGFR-TKIs have been reported in randomized controlled trials (RCTs). However, the incidence has varied substantially among clinical trials, and there has been no systematic attempt to synthesize the data in order to define the overall incidence and risk of infections associated with these drugs. Therefore, we conducted a systematic review and meta-analysis of RCTs to determine the overall risk of developing severe infection in cancer patients treated with these drugs.

Methods
=======

Data sources
------------

Studies were identified by searching the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed (up to December 2014), Web of Science, and EMBASE, including abstracts from the leading conference proceedings. The search was limited to prospective RCTs published in English. Keywords were sorafenib, nexavar, BAY43-9006, sunitinib, sutent, SU11248, pazopanib, votrient, GW786034, vandetanib, caprelsa, ZD6474, axitinib, AG-013736, cediranib, AZD2171, tivozanib, regorafenib, BAY 73-4506, cabozantinib, brivanib, ramucirumab, IMC-1121B, nintedanib, BIBF 1120, motesanib, randomized controlled trials, and cancer. The search strategy also used text terms such as angiogenesis inhibitors and vascular endothelial growth factor receptor-tyrosine kinase inhibitors to identify relevant information (Supplementary material). When more than one publication or presentation was identified from the same clinical trial, the most recent report with complete information about infectious events was included for analysis. The quality of reports of clinical trials was assessed and calculated using the five-item Jadad scale including randomization, double-blinding, and withdrawals.[@b34-ott-8-2361]

Study selection
---------------

The purpose of this study was to determine whether VEGFR-TKIs contribute to the development of severe and fatal infectious events in patients with cancer. Therefore, we only selected those randomized clinical trials that directly compared patients with cancer treated with and without VEGFR-TKIs for analysis. Clinical trials that met the following criteria were included: (1) prospective randomized controlled Phase II and III trials in cancer patients, (2) randomized assignment of patients to VEGFR-TKIs treatment or control in addition to current chemotherapy and/or biological agent, and (3) events or event rate and sample size available for high-grade (grade 3--4) and fatal (grade 5) infectious events. Phase I trials were excluded because of interstudy variability in drug dosing as well as the small number of patients in these trials. Study selection was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.[@b35-ott-8-2361]

Data extraction and clinical endpoints
--------------------------------------

Two investigators independently performed data extraction. Agreement between the two data extractors was assessed with the Kappa statistic test. The following information was recorded for each study: first author's name, year of publication, trial phase, number of patients enrolled, treatment arms, number of patients in treatment and controlled groups, underlying malignancy, median age, median progression-free survival and overall survival, adverse outcomes of interest (infectious events), and name and dosage of VEGFR-TKIs. The following adverse outcomes were considered as infectious events and were included in the analyses: infections (not specified), febrile neutropenia, sepsis, septic shock, fever, bacterial peritonitis, and pneumonia. Adverse events of severe infections (≥grade 3), as assessed and recorded according to the National Cancer Institute's common terminology criteria (version 2 or 3; <http://ctep.cancer.gov>), were extracted for analysis, which has been widely used in cancer clinical trials.

Statistical analysis
--------------------

The principal summary measures were incidence, Peto odds ratio (Peto OR), and corresponding 95% confidence intervals (CIs). For the calculation of incidence, the number of patients experiencing infections and total number of patients treated with VEGFR-TKIs were extracted from the safety profiles of all selected clinical trials; the proportion of patients with infections and 95% CIs were derived for each study.

We also calculated the Peto ORs and 95% CIs of infections in patients assigned to VEGFR-TKIs vs control treatment. For one study that reported zero events in the treatment or control arm, we applied the classic half-integer correction to calculate the relative risk (RR) and variance.[@b36-ott-8-2361] We also conducted the following prespecified subgroup analyses to find the potential risk factor of infections: tumor types, VEGFR-TKIs, and phase of trials. For each meta-analysis, the Cochran *Q* statistic and *I*^2^ score were first calculated to determine heterogeneity among the proportions of the included trials.[@b37-ott-8-2361] For *P*\<0.10 values of the Cochran *Q* statistic, the assumption of homogeneity was deemed invalid, and a random-effects model was reported. Otherwise, results from the fixed-effects model were reported. Additionally, we also calculated the number needed to harm from the absolute difference of the pooled estimates between the two groups. Finally, potential publication biases were evaluated with funnel plots for severe infections, which assessed the relative symmetry of individual study estimates around the overall estimate, followed by Begg's and Egger's tests. A two-tailed *P*-value of \<0.05 without adjustment for multiplicity was considered statistically significant. The leave-one-out procedure was also performed for primary endpoint analysis. A two-tailed *P*-value of \<0.05 was considered statistically significant. The results of the meta-analysis were reported as classic forest plots. All statistical analyses were performed by using Version 2 of the Comprehensive MetaAnalysis program (Biostat, Englewood, NJ, USA) and Open Meta-Analyst software version 4.16.12 (Tufts University).

Trial sequential analysis
-------------------------

Trial sequential analyses (TSAs) were performed post hoc to assess the risk of random errors and false-positive results, and to help clarify the need for additional trials. RR was used as effect estimate in a DerSimonian and Laid random-effects model. Zero-event trials were handled by adding 0.5 events to the two arms. We used two-sided tests, type I error set at 5% and power set at 80%. In the TSA based on all trials, the boundaries were calculated with a relative risk reduction set at an arbitrary level of 60% and with model variance-based heterogeneity correction. The incidence of severe infections in the control group was set at 3.3% for cancer patients. TSA was performed in TSA V.0.9 β (<http://www.ctu.dk/tsa/>).

Results
=======

Search results
--------------

Our search yielded 982 clinical studies relevant to VEGFR-TKIs (sunitinib, sorafenib, pazopanib, vandetanib, axitinib, cediranib, tivozanib, regorafenib, cabozantinib, nintedanib, brivanib, ramucirumab, and motesanib). After excluding review articles, Phase I studies, single-arm Phase II studies, case reports, meta-analyses, observation studies, duplicated RCTs, commentaries, letters, and RCTs without adequate infections data ([Figure 1](#f1-ott-8-2361){ref-type="fig"}), we selected 27 RCTs, including 24 Phase III and three Phase II trials, for the purpose of analysis ([Table 1](#t1-ott-8-2361){ref-type="table"}). A total of 16,488 patients from 27 clinical trials were included for analysis. The characteristics of patients and studies are listed in [Table 2](#t2-ott-8-2361){ref-type="table"}. Underlying malignancies included non-small-cell lung cancer (NSCLC) (ten trials),[@b38-ott-8-2361]--[@b47-ott-8-2361] colorectal cancer (three trials),[@b14-ott-8-2361],[@b48-ott-8-2361],[@b49-ott-8-2361] thyroid cancer (three trials),[@b50-ott-8-2361]--[@b52-ott-8-2361] HCC (two trials),[@b53-ott-8-2361],[@b54-ott-8-2361] advanced breast cancer (one trial),[@b55-ott-8-2361] urothelial cancer (one trial),[@b56-ott-8-2361] pancreatic cancer (one trial),[@b57-ott-8-2361] gastric cancer (one trial),[@b58-ott-8-2361] melanoma (one trial),[@b59-ott-8-2361] RCC (one trial),[@b60-ott-8-2361] acute myeloid leukemia (one trial),[@b61-ott-8-2361] castration-resistant prostate cancer (one trial),[@b62-ott-8-2361] and GIST (one trial).[@b15-ott-8-2361] When examining by agent, sorafenib was investigated in seven trials (2,964 patients), vandetanib in seven trials (4,223 patients), sunitinib in five trials (3,167 patients), cediranib in two trials (1,164 patients), regorafenib in two trials (956 patients), motesanib in one trial (1,072 patients), ramucirumab in one trial (1,253 patients), nintedanib in one trial (655 patients), and brivanib in one trial (502 patients). The Cohen--Kappa statistic for agreement between the two reviewers was 0.866 (95% CI: 0.80--0.93).

Trial quality
-------------

Randomized treatment allocation sequences were generated in all trials. Twenty-one trials were placebo-controlled and double-blinded. Follow-up time was generally adequate for each trial and included a period of approximately 2--4 weeks after end of therapy on trial. All the trials were of moderately high to high quality (Jadad score 3--5).

RR of severe and fatal infections
---------------------------------

Severe infections occurred in 484 out of 8,937 (3.8%) patients receiving VEGFR-TKIs. In the non-TKI group, severe infections occurred in 274 out of 7,767 (3.0%) patients. Subjects in the VEGFR-TKI group were at significantly higher risk of severe infections than subjects in the non-TKI group (OR 1.69, 95% CI: 1.45--1.96, *P*\<0.001; [Figure 2](#f2-ott-8-2361){ref-type="fig"}). There was no evidence of heterogeneity (*Q*=31.61, *P*=0.206, *I*^2^=17.76%). Fatal infections occurred in 52 out of 4,923 (1.0%) patients receiving VEGFR-TKIs. In the non-TKI group, fatal infections occurred in 26 out of 4,111 (0.8%) patients. There was significant difference in risk of fatal infections between subjects in the VEGFR-TKI group and those in the non-TKI group (OR 1.78, 95% CI: 1.13--2.81, *P*=0.013; [Figure 3](#f3-ott-8-2361){ref-type="fig"}), and there was no evidence of significant heterogeneity (*Q*=15.0, *P*=0.31, *I*^2^=13.4%). We also did sensitivity analysis to examine the stability and reliability of pooled severe ORs by sequential omission of individual studies. The results indicated that the significance estimate of pooled severe RRs was not significantly influenced by omitting any single study ([Figure 4](#f4-ott-8-2361){ref-type="fig"}).

Subgroup analysis of RR of severe infections
--------------------------------------------

To determine whether the observed increase in ORs of developing severe infections was the result of confounding bias, we performed subgroup analyses according to the underlying malignancy, VEGFR-TKIs, and phase of trials. When stratified by tumor types, a significantly increased risk of severe infections was observed in colorectal cancer (OR 1.99, 95% CI: 1.19--3.33, *P*=0.009) and NSCLC (OR 1.65, 95% CI: 1.39--1.96, *P*\<0.001), while the risk of severe infections was decreased in HCC (OR 0.52, 95% CI: 0.10--2.65, *P*=0.44; [Table 1](#t1-ott-8-2361){ref-type="table"}). However, no significant differences in ORs of severe infections were found among these tumor types (*P*=0.85). Clinicians should be cautious when interpreting these results due to the limited RCTs of HCC and colorectal cancer included for the OR calculation.

The risk of severe infections might be related to different VEGFR-TKIs. Our results demonstrated that the use of sorafenib (OR 2.11, 95% CI: 1.48--3.00, *P*\<0.011 and sunitinib (OR 2.18, 95% CI: 1.35--3.53, *P*=0.001) significantly increased the risk of severe infections, while a nonsignificantly increased risk of severe infections was observed in vandetanib, cediranib, and regorafenib ([Table 1](#t1-ott-8-2361){ref-type="table"}). Again, no significant differences in ORs of severe infections were found among these drugs (*P*=0.48). Then, we also carried out a subgroup risk analysis stratified according to phase of trials (Phase II vs Phase III). Patients from Phase III trials had an OR of 1.71 (95% CI: 1.47--1.99, *P*\<0.001), while patients from Phase II studies had an OR of 1.21 (95% CI: 0.60--2.44, *P*=0.60; [Table 1](#t1-ott-8-2361){ref-type="table"}).

TSA assessed the effect of VEGFR-TKIs on severe infections in cancer patients and showed that the required information size was 3,259 which was less than that in our study (n=16,488), and the cumulative *Z*-curve crossed the trial sequential monitoring boundary for harm, indicating that further studies are unlikely to change the current conclusion ([Figure 5](#f5-ott-8-2361){ref-type="fig"}).

Risk of severe and fatal infections by specific types
-----------------------------------------------------

Individual specified and nonspecified causes of severe and fatal infections are listed in [Table 3](#t3-ott-8-2361){ref-type="table"}. Of those severe infections that were specified, the most common events for severe infections were febrile neutropenia (61.6%). We then calculated the risk of severe infections stratifying trials according to specific type of severe infections. Our results showed that the use of VEGFR-TKIs significantly increased the risk of severe febrile neutropenia (OR 1.57, 95% CI: 1.30--1.88, *P*\<0.001), pneumonia (OR 1.79, 95% CI: 1.29--2.49, *P*\<0.001), fever (OR 5.35, 95% CI: 1.47--19.51, *P*=0.011), and sepsis (OR 3.68, 95% CI: 1.51--8.99, *P*=0.004). We also calculated the risk of fatal infections stratifying trials according to specific types of infections; the use of VEGFR-TKIs significantly increased the risk of fatal sepsis (OR 3.66, 95% CI: 1.47--9.13, *P*=0.005) but not fatal pneumonia (OR 1.34, 95% CI: 0.80--2.25, *P*=0.26; [Table 1](#t1-ott-8-2361){ref-type="table"}).

Publication bias
----------------

A funnel plot and both Begg's and Egger's tests were performed to assess the publication bias of the selected studies. The shapes of the funnel plots showed no evidence of obvious asymmetry (*P*=0.61 for OR of severe infections; [Figure 6](#f6-ott-8-2361){ref-type="fig"}). The results from Egger's test were not significant (*P*=0.58).

Discussion
==========

During the past decade, identification of the importance of VEGF signal pathway in tumor growth, invasion, and metastasis has led to the development of VEGFR-targeted treatments, which has significantly changed the prognosis of several solid tumors including RCC, HCC, colorectal cancer, and thyroid cancer. Although VEGFR-TKIs are generally well tolerated, infection is an emerging complication with the use of these drugs. Infections can delay treatment or reduce patient compliance with VEGFR-TKI therapies, and the management of infections also increases the cost of cancer treatment. Thus, it is particularly important for all health care practitioners and patients to understand and recognize the risk of infection associated with VEGFR-TKI therapies.

To the best of our knowledge, this is the first and largest meta-analysis evaluating the risk of infections associated with VEGFR-TKIs. In this comprehensive analysis of 16,488 patients, 27 randomized Phase II and III trials using VEGFR-TKIs (sunitinib, sorafenib, pazopanib, axitinib, vandetanib, cediranib, ramucirumab, regorafenib, nintedanib, and motesanib) were included. We did not include Phase I trials in our meta-analysis, since these studies are not randomized and include a wide range of different dosages of drugs. We observed a significant 1.69-fold increase in the risk of high grades of infections with VEGFR-TKIs compared to controls not receiving VEGFR-TKIs. Sensitivity analysis demonstrated that the significance estimate of pooled severe ORs was not significantly influenced by omitting any single study. We also investigated the outcome of VEGFR-TKIs-associated severe infections; our results showed that the use of VEGFR-TKIs significantly increased the risk of fatal infections when compared to non-VEGFR-TKI regimens (*P*=0.013). However, given that the absolute risk of fatal infections is low, the use of VEGFR-TKIs should be considered in the context of overall survival benefits. As VEGFR-TKIs are increasingly used in cancer patients, it is particularly important for clinicians to understand and recognize the risk of severe and fatal infection.

Given an increased OR of treatment-related infections, it is clear that proper monitoring, immediate intervention, and effective management are crucial to achieve the maximal therapeutic benefit of VEGFR-TKIs. However, there are no specific guidelines for the treatment of VEGFR-TKIs-induced infections because there is a lack of controlled studies addressing the subject. Based on our findings, the following approaches may be considered to reduce the association of VEGFR-TKIs with risk of infections. Before the initiation of VEGFR-TKIs, clinicians must fully treat patients with any active infection and must monitor patients during the course of VEGFR-TKIs treatment. Clinicians should be cautious when adding VEGFR-TKIs, especially sorafenib and sunitinib, to the first-line or second-line therapies for the treatment of NSCLC and colorectal cancers.

Despite the size of this meta-analysis, our study has some limitations. First, this was a trial-level meta-analysis, and confounding variables at the patient level, such as comorbidities, younger age, prior cardiac history, and previous chemotherapeutic exposure, could not be incorporated into the analysis. However, all of the included trials exhibited moderate- or good-quality Jadad scores, and a report suggests that trial-level and patient-level meta-analyses yield similar results. Second, although most of these trials carried out the randomization process adequately, the infectious events are retrospectively collected. Therefore, these data should be interpreted cautiously because the extracted data used for this analysis could not be considered randomized, which somehow compromised the evidence level. Finally, our literature search is limited to articles published in English creating some selection bias. However, our research detects no publication bias using Begg and Egger tests for ORs of severe and fatal infections.

Conclusion
==========

The use of small-molecule VEGFR-TKIs is associated with an increase in the risk of developing severe and fatal infectious events in cancer patients. Close monitoring for any sign of infections is recommended, especially in NSCLC and colorectal cancer patients. Nevertheless, for the average patient, these approved drugs do improve clinical outcomes in their respective indications, and the benefits generally outweigh the risks.

Supplementary materials
=======================

Search strategy for meta-analysis of association between use of vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) and the risk of severe infections in cancer Patients
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### PubMed

1.  VEGFR-TKIs \[ALL\]

2.  "VEGFR-tyrosine kinase inhibitors" \[ALL\]

3.  "VEGFR-tyrosine kinase inhibitor" \[ALL\]

4.  "vascular endothelial growth factor receptor tyrosine kinase inhibitor" \[ALL\]

5.  "vascular endothelial growth factor receptor tyrosine kinase inhibitors" \[ALL\]

6.  or 2 or 3 or 4 or 5

7.  "nexavar" \[NM\] OR "BAY43-9006" \[NM\] OR "sorafenib" \[ALL\]

8.  "sutent" \[NM\] OR "SU11248" \[NM\] OR "sunitinib" \[ALL\]

9.  "votrient" \[NM\] OR"GW786034" \[NM\] OR "vandetanib" \[ALL\]

10. "caprelsa" \[NM\] OR "ZD6474" \[NM\] OR "axitinib" \[ALL\]

11. "AG-013736" \[MH\] OR "cediranib" \[ALL\]

12. "AZD2171" \[NM\] OR "tivozanib" \[ALL\]

13. "BAY73-4506" \[MH\] OR "regorafenib" \[ALL\]

14. "cabozantinib" \[ALL\]

15. "brivanib" \[ALL\]

16. "ramucirumab" \[ALL\]

17. "IMC-1121B" \[NM\] OR "nintedanib" \[ALL\]

18. "BIBF1120" \[MH\] OR "motesanib" \[ALL\]

19. or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18

20. "neoplasms" \[MH\] OR "neoplasms" \[ALL\] OR "cancer" \[ALL\]

21. "neoplasm" \[ALL\]

22. "neoplasia" \[ALL\]

23. "malignancy" \[ALL\]

24. Malignant \[ALL\]

25. "carcinoma" \[MH\] OR "carcinoma" \[ALL\]

26. "glioma" \[MH\] OR "glioma" \[ALL\]

27. "leukaemia" \[ALL\] OR "leukemia" \[MH\] OR "leukemia" \[ALL\]

28. "lymphoma" \[MH\] OR "lymphoma" \[ALL\]

29. "melanoma" \[MH\] OR "melanoma" \[ALL\]

30. "meningioma" \[MH\] OR "meningioma" \[ALL\]

31. "sarcoma" \[MH\] OR "sarcoma" \[ALL\]

32. or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31

33. and 32

34. "humans" \[MH\]

35. and 34

ALL = all fields, MH = MeSH Terms, NM = substance name

Limitation: humans

Date of Search: December 2014 (1974--December 2014)

### EMBASE

1.  VEGFR-TKIs

2.  "VEGFR- tyrosine kinase inhibitors"

3.  "VEGFR- tyrosine kinase inhibitor"/de

4.  "vascular endothelial growth factor receptor tyrosine kinase inhibitor"/de

5.  "vascular endothelial growth factor receptor tyrosine kinase inhibitors"/de

6.  or 2 or 3 or 4 or 5

7.  "sunitinib"/de

8.  "sorafenib"/de

9.  "pazopanib"/de

10. "vandetanib"/de

11. "axitinib"/de

12. "cediranib"/de

13. "tivozanib"/de

14. "regorafenib"/de

15. "cabozantinib"/de

16. "nintedanib"/de

17. "brivanib"/de

18. "ramucirumab"/de

19. "motesanib"/de

20. or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19

21. "cancer"/de

22. "neoplasm"/de

23. "neoplasia"/de

24. malignancy

25. malignant

26. "carcinoma"/de

27. "glioma"/de

28. "leukemia"/de

29. "lymphoma"/de

30. "melanoma"/de

31. "meningioma"/de

32. "sarcoma"/de

33. or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32

34. \[humans\]/lim

35. \[embase\]/lim OR \[embase classic\]/lim

36. and 34 and 35

/de = Mapped terms,/lim = Limitation

Limitation: humans

Date of Search: December 2014 (1979--December 2014)

### CENTRAL database (The Cochrane Library)

1.  VEGFR-TKIs \[ALL\]

2.  "VEGFR-tyrosine kinase inhibitors" \[ALL\]

3.  "VEGFR-tyrosine kinase inhibitor" \[ALL\]

4.  "vascular endothelial growth factor receptor tyrosine kinase inhibitor" \[ALL\]

5.  "vascular endothelial growth factor receptor tyrosine kinase inhibitors" \[ALL\]

6.  or 2 or 3 or 4 or 5

7.  "sunitinib"/de

8.  "sorafenib"/de

9.  "pazopanib"/de

10. "vandetanib"/de

11. "axitinib"/de

12. "cediranib"/de

13. "tivozanib"/de

14. "regorafenib"/de

15. "cabozantinib"/de

16. "nintedanib"/de

17. "brivanib"/de

18. "ramucirumab"/de

19. "motesanib"/de

20. or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19

21. "cancer"/de

22. "neoplasm"/de

23. "neoplasia"/de

24. malignancy

25. malignant

26. "carcinoma"/de

27. "glioma"/de

28. "leukemia"/de

29. "lymphoma"/de

30. "melanoma"/de

31. "meningioma"/de

32. "sarcoma"/de

33. or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32

34. and 33

\[ALL\] = in All Text

Limitation: none

Date of Search: December 2014 (1979--December 2014)
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![Selection process for prospective randomized controlled trials included in the meta-analysis.\
**Abbreviation:** RCT, randomized controlled trial.](ott-8-2361Fig1){#f1-ott-8-2361}

![Peto odds ratio of severe infections associated with VEGFR-TKIs vs control.\
**Abbreviations:** VEGFR-TKIs, vascular endothelial growth factor receptor tyrosine kinase inhibitors; CI, confidence interval.](ott-8-2361Fig2){#f2-ott-8-2361}

![Peto odds ratio of fatal infections associated with VEGFR-TKIs vs control.\
**Abbreviations:** VEGFR-TKIs, vascular endothelial growth factor receptor tyrosine kinase inhibitors; CI, confidence interval.](ott-8-2361Fig3){#f3-ott-8-2361}

![Meta-analysis of severe infections associated with VEGFR-TKIs vs control: "leave-one-out" sensitivity analysis.\
**Abbreviations:** VEGFR-TKIs, vascular endothelial growth factor receptor tyrosine kinase inhibitors; CI, confidence interval.](ott-8-2361Fig4){#f4-ott-8-2361}

![Trial sequential analysis of 27 trials with lower risk of bias reporting severe infections.\
**Abbreviation:** VEGFR-TKIs, vascular endothelial growth factor receptor tyrosine kinase inhibitors.](ott-8-2361Fig5){#f5-ott-8-2361}

![Funnel plot of standard error by log-risks ratio for severe infections.](ott-8-2361Fig6){#f6-ott-8-2361}

###### 

Relative risk of severe infectious events according to tumor types, VEGFR-TKIs, and phases of trials

  Groups                 Studies, n   Severe infectious events, n/total, n   RR (95% CI)   *P*-value            Numbers needed to harm   *P*-value for group difference   
  ---------------------- ------------ -------------------------------------- ------------- -------------------- ------------------------ -------------------------------- ------
  **Tumor types**                                                                                                                                                         
  NSCLC                  10           362/4,891                              210/4,597     1.65 (1.39--1.96)    \<0.001                  35                               0.85
  CRC                    3            43/1,389                               19/995        1.99 (1.19--3.33)    0.009                    84                               
  Thyroid cancer         3            6/510                                  1/381         3.57 (0.78--16.33)   0.10                     109                              
  HCC                    2            2/293                                  4/302         0.52 (0.10--2.65)    0.44                     155                              
  Others                 9            71/1,854                               40/1,492      1.73 (1.17--2.56)    0.006                    87                               
  **VEGFR-TKIs**                                                                                                                                                          
  Vandetanib             7            111/2,387                              69/1,936      1.25 (0.92--1.70)    0.16                     92                               0.48
  Sorafenib              7            87/1,467                               43/1,497      2.11 (1.48--3.00)    \<0.001                  33                               
  Sunitinib              5            52/1,732                               23/1,435      2.18 (1.35--3.53)    0.001                    72                               
  Cediranib              2            14/653                                 8/511         1.56 (0.66--3.65)    0.31                     174                              
  Regorafenib            2            9/637                                  2/319         1.99 (0.57--7.02)    0.28                     128                              
  Others                 4            211/2,061                              129/2,069     1.62 (1.32--2.00)    \<0.001                  25                               
  **Phases of trials**                                                                                                                                                    
  Phase II               4            22/680                                 15/424        1.21 (0.60--2.44)    0.60                     336                              0.29
  Phase III              23           462/8,257                              259/7,343     1.71 (1.47--1.99)    \<0.001                  48                               
  Overall                27           484/8,937                              274/7,767     1.69 (1.45--1.96)    \<0.001                  53                               NA

**Abbreviations:** VEGFR-TKIs, vascular endothelial growth factor receptor tyrosine kinase inhibitors; RR, relative risk; CI, confidence interval; NSCLC, non-small-cell lung cancer; CRC, colorectal cancer; HCC, hepatocellular carcinoma; NA, not available.

###### 

Baseline characteristics of 27 randomized controlled trials in the meta-analysis (n=1,488)

  Authors (year)                             Histology           Phase     Patients enrolled        Treatment arm                              Median age (years)   Median PFS (months)   Median OS (months)   Number for analysis   Severe infections     Reported infectious events
  ------------------------------------------ ------------------- --------- ------------------------ ------------------------------------------ -------------------- --------------------- -------------------- --------------------- --------------------- -------------------------------------------------------------------------
  Natale et al (2009)[@b47-ott-8-2361]       NSCLC               III       168                      Vandetanib 300 mg                          61                   2.6                   6.1                  83                    3                     Pneumonia, sepsis
                                                                           Gefitinib                63                                         1.9                  7.4                   85                   0                                           
  Herbst et al (2010)[@b46-ott-8-2361]       NSCLC               III       1,391                    Vandetanib 100 mg qd po + Doc              59                   4                     10.3                 689                   46                    Febrile neutropenia
                                                                           Placebo + Doc            59                                         3.2                  9.9                   690                  38                                          
  Barrios et al (2010)[@b55-ott-8-2361]      ABC                 III       482                      Sunitinib 37.5 mg qd po                    53                   2.8                   15.3                 238                   1                     Septic shock
                                                                           Capecitabine             53                                         4.2                  24.6                  240                  0                                           
  Scagliotti et al (2010)[@b45-ott-8-2361]   NSCLC               III       926                      Sorafenib 400 mg bid po + PTX + CBP        62                   4.6                   10.7                 436                   38                    Febrile neutropenia, pneumonia, infections
                                                                           Placebo + PTX + CBP      63                                         54                   10.6                  459                  12                                          
  Abou-Alfa et al (2010)[@b54-ott-8-2361]    HCC                 II        96                       Doxorubicin + sorafenib 400 mg bid po qd   66                   6                     13.7                 47                    0                     Febrile neutropenia
                                                                           Doxorubicin + placebo    65                                         2.7                  6.5                   49                   4                                           
  Natale et al (2011)[@b44-ott-8-2361]       NSCLC               III       1,240                    Vandetanib 300 mg qd po                    61                   2.6                   6.8                  623                   9                     Pneumonia
                                                                           Erlotinib                61                                         2                    7.7                   614                  5                                           
  Leboulleux et al (2012)[@b52-ott-8-2361]   Thyroid cancer      II        145                      Vandetanib 300 mg qd po                    63                   11.1                  NR                   72                    1                     Pneumonia
                                                                 Placebo   64                       5.9                                        NR                   73                    1                                                                
  Lee et al (2012)[@b43-ott-8-2361]          NSCLC               III       924                      Vandetanib 300 mg qd po                    60                   1.9                   8.5                  619                   47                    Infections, pneumonia
                                                                           Placebo                  60                                         1.8                  7.8                   303                  21                                          
  Wells et al (2012)[@b51-ott-8-2361]        Thyroid cancer      III       331                      Vandetanib 300 mg qd po                    50.7                 30.5                  NR                   231                   2                     Aspiration, pneumonia, staphylococcal sepsis
  Placebo                                    53.4                19.3      NR                       99                                         0                                                                                                           
  Choueiri et al (2012)[@b56-ott-8-2361]     Urothelial cancer   III       142                      Vandetanib 100 mg qd po q3w + Doc          NR                   2.56                  5.85                 70                    3                     Infections
  Placebo + Doc                              NR                  1.58      7.03                     72                                         4                                                                                                           
  Goncalves et al (2012)[@b57-ott-8-2361]    Pancreatic cancer   III       104                      Sorafenib 400 mg bid pos + gemcitabine     64                   3.8                                        52                    0                     Febrile neutropenia
  Gemcitabine                                64                  5.7                                52                                         2                                                                                                           
  Scagliotti et al (2012)[@b41-ott-8-2361]   NSCLC               III       1,090                    Motesanib 125 mg qd po + PTX + CBP         60                   5.6                   13                   533                   43                    Febrile neutropenia, pneumonia
                                                                           Placebo + PTX + CBP      60                                         5.4                  11                    539                  22                                          
  Yi et al (2012)[@b58-ott-8-2361]           Gastric cancer      II        107                      Sunitinib 37.5 mg qd po + Doc              54                   3.9                   8                    56                    15                    Febrile neutropenia
  Doc                                        52                  2.6       6.6                      49                                         8                                                                                                           
  Hoff et al (2012)[@b49-ott-8-2361]         CRC                 III       860                      Cediranib 20 mg qd po + chemotherapy       58                   8.6                   19.7                 500                   5                     Pneumonia, septic shock
                                                                           Placebo + chemotherapy   59                                         8.3                  18.9                  358                  3                                           
  Scagliotti et al (2012)[@b42-ott-8-2361]   NSCLC               III       960                      Sunitinib 37.5 mg qd po + erlotinib        61                   3.6                   9                    473                   1                     Respiratory tract infection
  Erlotinib                                  61                  2         8.5                      477                                        0                                                                                                           
  Carrato et al (2013)[@b48-ott-8-2361]      CRC                 III       768                      Sunitinib 37.5 mg qd po + FOLFIRI          59                   7.8                   20.3                 384                   32                    Neutropenic sepsis, febrile neutropenia, pneumonia, sepsis/septic shock
                                                                           Placebo + FOLFIRI        58                                         8.4                  19.8                  384                  14                                          
  Grothey et al (2013)[@b14-ott-8-2361]      CRC                 III       1,052                    Regorafenib 160 mg qd po                   61                                         6.4                  505                   6                     Fever, pneumonia
                                                                           Placebo                  61                                                              5                     253                  2                                           
  Demetri et al (2013)[@b15-ott-8-2361]      GIST                III       199                      Regorafenib 160 mg qd po                   60                   4.8                   NR                   132                   3                     Fever
                                                                           Placebo                  61                                         0.9                  NR                    66                   0                                           
  Serve et al (2013)[@b61-ott-8-2361]        AML                 III       162                      Sorafenib 400 mg bid po + chemotherapy     NR                   7                     15                   80                    15                    Pneumonia, sepsis
                                                                           Placebo + chemotherapy   NR                                         5                    13                    82                   4                                           
  Flaherty et al (2013)[@b59-ott-8-2361]     Melanoma            III       823                      Sorafenib 400 mg bid po + PTX + CBP        66                   4.9                   11.3                 393                   24                    Febrile neutropenia
                                                                           Placebo + PTX + CBP      61                                         4.2                  11.1                  397                  16                                          
  Brose et al (2014)[@b50-ott-8-2361]        Thyroid cancer      III       417                      Sorafenib 400 mg bid po                    63                   10.8                  NR                   207                   3                     Fever
                                                                           Placebo                  63                                         5.8                  NR                    209                  0                                           
  Garon et al (2014)[@b40-ott-8-2361]        NSCLC               III       1,253                    Ramucirumab 10 mg/kg + Doc                 62                   4.5                   10.5                 627                   100                   Febrile neutropenia
                                                                           Placebo + Doc            61                                         3                    9.1                   618                  62                                          
  Kudo et al (2014)[@b53-ott-8-2361]         HCC                 III       502                      Brivanib 800 mg qd + TACE                  57                   12                    26.4                 246                   2                     Bacterial peritonitis,
                                                                           Placebo + TACE           59                                         10.9                 26.1                  253                  0                     pulmonary infection   
  Laurie et al (2014)[@b39-ott-8-2361]       NSCLC               III       306                      Cediranib 20 mg qd po + PTX + CBP          63                   5.5                   12.2                 153                   9                     Febrile neutropenia
                                                                           Placebo + PTX + CBP      62                                         5.5                  12.1                  153                  5                                           
  Reck et al (2014)[@b38-ott-8-2361]         NSCLC               III       655                      Nintedanib 200 mg bid po + Doc             60                   3.4                   10.9                 655                   66                    Febrile neutropenia
                                                                           Placebo + Doc            60                                         2.7                  7.9                   659                  45                                          
  Hutson et al (2014)[@b60-ott-8-2361]       RCC                 III       512                      Sorafenib 400 mg bid po                    61                   3.9                   16.6                 252                   7                     Pneumonia
                                                                           Temsirolimus             60                                         4.3                  12.3                  249                  5                                           
  Michaelson et al (2014)[@b62-ott-8-2361]   CRPC                III       873                      Sunitinib 37.5 mg qd po + prednisone       69                   5.6                   13.1                 581                   3                     Pneumonia, sepsis
                                                                           Placebo + prednisone     68                                         4.1                  11.8                  285                  1                                           

**Abbreviations:** PFS, progression-free survival; OS, overall survival; NSCLC, non-small-cell lung cancer; qd, once daily; po, per oral; Doc, docetaxel; ABC, advanced breast cancer; bid, twice daily; PTX, paclitaxel; CBP, carboplatin; HCC, hepatocellular carcinoma; NR, not reported; q3w, every 3 weeks; CRC, colorectal cancer; FOLFIRI, folinic acid (leucovorin), fluorouracil, and irinotecan; GIST, gastrointestinal stromal tumor; AML, acute myeloid leukemia; TACE, transcatheter arterial chemoembolization; RCC, renal cell carcinoma; CRPC, castration-resistant prostate cancer.

###### 

Severe and fatal infectious events with VEGFR-TKIs by specific types

                          Infectious events, n/total, n   RR (95% CI)   *P*-value            
  ----------------------- ------------------------------- ------------- -------------------- --------
  **Severe infections**                                                                      
  Unspecified             57/1,125                        28/834        1.53 (0.98--2.39)    0.062
  Febrile neutropenia     298/4,025                       195/4,049     1.57 (1.30--1.88)    ,0.001
  Pneumonia               102/6,273                       48/5,172      1.79 (1.29--2.49)    ,0.001
  Fever                   10/844                          0/528         5.35 (1.47--19.51)   0.011
  Sepsis                  17/2,097                        3/1,533       3.68 (1.51--8.99)    0.004
  **Fatal infections**                                                                       
  Pneumonia               36/4,685                        24/3,871      1.34 (0.80--2.25)    0.26
  Sepsis                  16/1,866                        3/1,434       3.66 (1.47--9.13)    0.005
  Overall                 52/4,923                        27/4,111      1.78 (1.13--2.81)    0.013

**Abbreviations:** VEGFR-TKIs, vascular endothelial growth factor receptor tyrosine kinase inhibitors; RR, relative risk; CI, confidence interval.
